You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,871,224


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,871,224
Title:Botulinum toxin therapy for skin disorders
Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.
Inventor(s): First; Eric (Morristown, NJ)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/073,741
Patent Claims:1. A method for treating a keloid in a patient in need thereof, the method comprising the step of administering a therapeutically effective amount of a botulinum toxin complex to the keloid, to thereby treat the keloid; wherein the therapeutically effective amount administered is less than an amount used to paralyze a muscle, ranging between about 10.sup.-3 units/kg of patient weight and about 35 units/kg of patient weight, and which reduces the keloid in size by from about 20% to 100%.

2. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

3. The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.

4. The method of claim 1, wherein the administration is by topical or subcutaneous administration of the botulinum toxin.

5. The method of claim 1, wherein administration of a botulinum toxin type A is no less than about 1 to about 200 units per patient treatment session.

6. The method of claim 2 wherein administration of a botulinum toxin type B is no less than about 40 to about 2500 units per patient treatment session.

7. A method for treating a symptom associated with a keloid in a patient in need thereof, the method comprising the step of administering a therapeutically effective amount of a botulinum toxin complex to the keloid, thereby treating the symptom associated with the keloid, wherein the therapeutically effective amount administered is less than an amount used to paralyze a muscle, ranging between about 10.sup.-3 units/kg of patient weight and about 35 units/kg of patient weight, and which reduces the keloid in size by from about 20% to 100%.

8. The method of claim 7, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

9. The method of claim 7, wherein the administration is by injection directly to the keloid.

10. The method of claim 7, wherein the symptom is selected from the group consisting of pain, inflammation and vascularization.

11. The method of claim 7, wherein administration is transdermal or subdermal or intradermal.

12. The method of claim 7, wherein the administration is by a botulinum toxin implant.

13. The method of claim 7, wherein administration of a botulinum toxin type A is no less than about 1 to about 200 units per administration site, per patient treatment session.

14. The method of claim 7, wherein administration of a botulinum toxin type B is no less than about 40 to about 2500 units per administration site, per patient treatment session.

15. A method for treating a keloid in a patient in need thereof, the method comprising the step of administering a dose of a botulinum toxin complex type A, to the keloid of the patient; wherein the dose administered is less than an amount used to paralyze a muscle, ranging between about 10.sup.-3 units/kg of patient weight and about 35 units/kg of patient weight, and which reduces the keloid in size by from about 20% to 100%.

16. The method of claim 15, wherein the administration is by injection directly to the keloid.

17. The method of claim 15, wherein the administration is by topical or subcutaneous administration of the botulinum toxin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.